Booster Ketamine Sessions vs. Monthly Maintenance Infusions

Booster ketamine sessions and monthly maintenance infusions are the two common follow-up strategies after an initial course of ketamine treatment, and they differ in one key way: boosters are given when symptoms return, while maintenance infusions run on a fixed schedule whether or not symptoms have come back. Most ketamine clinics decide between the two based on how long your remission lasted after the first series, not by default policy. A booster is a single, reactive infusion triggered by relapse signs, so the gap between sessions can run anywhere from a few weeks to several months. Monthly maintenance follows a set calendar, commonly every 2 to 6 weeks, functioning as ongoing relapse prevention rather than a response to a specific dip. Neither pattern has an FDA-approved protocol for generic (racemic) intravenous or intramuscular ketamine, since that use remains off-label for depression and other mental health conditions in 2026, so the decision is made case by case with your prescriber.

What Each Term Actually Means in Practice

A booster session is typically the same infusion protocol used during your initial series, given once, triggered by the return of symptoms rather than by the calendar. If your depression stayed in remission for ten weeks after your last induction infusion and then started creeping back, a booster is the single session meant to push it back into remission, after which you return to no scheduled treatment until symptoms resurface again.

A monthly maintenance infusion is part of an ongoing series with a fixed interval set in advance, often every 2 to 6 weeks depending on the clinic and your response, and it continues regardless of whether you're currently symptomatic. Clinics that offer both at-home telehealth and in-person options may structure maintenance differently depending on the setting; see IV ketamine vs at-home ketamine for how delivery method affects how maintenance visits are scheduled and monitored.

What the Research Says About Relapse Without Follow-Up Care

Ketamine's antidepressant effect from a single infusion typically fades within one to two weeks, which is why an initial treatment course usually involves multiple infusions rather than one. Researchers studying what happens after that initial series report that symptoms often return within weeks for a meaningful share of patients if no further treatment follows, which is a main reason most prescribers recommend some form of follow-up rather than stopping after induction. A 2019 trial supporting esketamine's FDA approval, published in JAMA Psychiatry and known as SUSTAIN-1, found that patients in stable remission who continued esketamine plus an oral antidepressant had a longer time to relapse than those switched to a placebo nasal spray plus the oral antidepressant alone. That trial tested scheduled continuation, not as-needed boosters, and no published study has directly compared the two approaches against each other, so claims that one strategy prevents relapse better than the other are not yet backed by head-to-head evidence.

This evidence gap matters for how you think about the decision: it's a clinical judgment call informed by your own relapse pattern, not a tested protocol with a clear winner. The same uncertainty applies when comparing ketamine maintenance to other long-term options; see ketamine vs. antidepressants for how indefinite dosing schedules compare across both approaches.

When a Fixed Monthly Schedule Tends to Fit Better

Scheduled maintenance tends to make more sense when your relapse pattern has been short and predictable rather than occasional. Signs that point toward monthly infusions over as-needed boosters include:

• Symptoms returned within two to three weeks every time treatment was spaced out further
• Several antidepressant trials failed before ketamine, suggesting a harder-to-stabilize baseline
• A history of suicidal ideation that your care team wants to monitor closely and consistently
• You and your prescriber already tried spacing out boosters and found the gaps too unpredictable to manage safely

The tradeoff is cost and exposure: a fixed schedule means paying for infusions during months when you might not have relapsed anyway, and more cumulative ketamine exposure over a year than a reactive approach. If a maintenance infusion doesn't seem to be working as well as earlier sessions did, raise that directly with your provider; see questions to ask when a follow-up dose isn't working for how to talk through a plateau or diminishing response.

How Esketamine's Approved Schedule Differs From IV Ketamine Maintenance

Esketamine (Spravato) is the only ketamine-based treatment with an FDA-approved maintenance schedule. Esketamine is the S-enantiomer of ketamine, delivered as a nasal spray under direct observation in a certified healthcare setting, and its label specifies an induction phase followed by a maintenance phase in which dosing frequency is reduced and then individualized based on response. Generic intravenous or intramuscular ketamine used for depression, anxiety, or other off-label mental health indications has no equivalent FDA-reviewed schedule. Each clinic sets its own booster or maintenance intervals based on clinical experience, which means the interval that counts as standard can vary noticeably between providers even for similar patients. If you're weighing the two forms directly, see ketamine vs. esketamine for how the approved and off-label pathways differ beyond maintenance scheduling.

Cost and Insurance Differences Between the Two Approaches

Booster sessions are typically billed per infusion, similar to pricing for your original induction series, so your annual cost tracks how often you actually relapse. Monthly maintenance means a recurring charge on a set calendar, which some clinics discount through package or subscription pricing, but the total can run higher over a year if your remission would have lasted longer without the fixed schedule. Compare how clinics structure these costs in sliding-scale vs. flat-fee ketamine pricing before committing to either pattern.

Insurance coverage is inconsistent for both. Esketamine maintenance is sometimes covered under medical benefits when a patient meets treatment-resistant depression criteria and the clinic follows the FDA-required Spravato Risk Evaluation and Mitigation Strategy (REMS) program, though prior authorization and documentation requirements are common. Generic IV ketamine for depression remains off-label, so neither boosters nor monthly maintenance are reliably covered, and many patients pay out of pocket regardless of which schedule they choose.

How to Decide With Your Provider

Track your symptoms for several weeks after your initial induction series ends, noting roughly when, if at all, they start returning. That timeline is the single most useful piece of information for choosing between boosters and monthly maintenance: a remission that lasted two months points toward as-needed boosters, while a remission that barely lasted two weeks points toward a fixed schedule. Bring that log to your follow-up visit and ask your provider to walk through both options against your specific pattern rather than defaulting to whatever the clinic typically offers.

Who makes this call also matters. See nurse practitioner vs. psychiatrist ketamine clinics for how prescriber background can affect how maintenance decisions are made, and review questions to ask about continuity of care before committing to either pattern long-term. If you haven't yet had your first consultation, raising your goals early, including how you'd prefer to handle follow-up care, helps set expectations; see questions about treatment goals for your first consultation for a starting list. This article is educational and not a substitute for individualized medical advice from a licensed clinician.